Ligand Pharmaceuticals Incorporated (LGND) Shares Bought by Willingdon Wealth Management
Willingdon Wealth Management boosted its stake in shares of Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) by 1.4% during the second quarter, according to its most recent filing with the SEC. The firm owned 14,204 shares of the biotechnology company’s stock after buying an additional 193 shares during the period. Willingdon Wealth Management owned approximately 0.07% of Ligand Pharmaceuticals worth $1,724,000 as of its most recent filing with the SEC.
Several other institutional investors have also recently added to or reduced their stakes in LGND. Independent Portfolio Consultants Inc. boosted its position in Ligand Pharmaceuticals by 1.0% in the first quarter. Independent Portfolio Consultants Inc. now owns 1,555 shares of the biotechnology company’s stock valued at $165,000 after buying an additional 15 shares during the last quarter. First Mercantile Trust Co. boosted its position in shares of Ligand Pharmaceuticals by 1.6% in the second quarter. First Mercantile Trust Co. now owns 1,310 shares of the biotechnology company’s stock worth $159,000 after buying an additional 20 shares in the last quarter. State of Alaska Department of Revenue boosted its position in shares of Ligand Pharmaceuticals by 1.9% in the first quarter. State of Alaska Department of Revenue now owns 2,100 shares of the biotechnology company’s stock worth $222,000 after buying an additional 40 shares in the last quarter. Municipal Employees Retirement System of Michigan boosted its position in shares of Ligand Pharmaceuticals by 0.9% in the first quarter. Municipal Employees Retirement System of Michigan now owns 4,350 shares of the biotechnology company’s stock worth $460,000 after buying an additional 40 shares in the last quarter. Finally, Eqis Capital Management Inc. boosted its position in shares of Ligand Pharmaceuticals by 0.6% in the second quarter. Eqis Capital Management Inc. now owns 8,609 shares of the biotechnology company’s stock worth $1,045,000 after buying an additional 51 shares in the last quarter.
Ligand Pharmaceuticals Incorporated (NASDAQ:LGND) opened at 124.05 on Friday. Ligand Pharmaceuticals Incorporated has a one year low of $87.50 and a one year high of $129.94. The company has a market capitalization of $2.61 billion, a PE ratio of 302.56 and a beta of 0.96. The company has a 50-day moving average price of $122.91 and a 200-day moving average price of $113.41.
Ligand Pharmaceuticals (NASDAQ:LGND) last released its quarterly earnings data on Monday, August 7th. The biotechnology company reported $0.67 earnings per share (EPS) for the quarter, topping the consensus estimate of $0.25 by $0.42. Ligand Pharmaceuticals had a net margin of 7.39% and a return on equity of 5.05%. The company had revenue of $28 million during the quarter, compared to the consensus estimate of $24.40 million. During the same period in the previous year, the firm earned $0.50 earnings per share. Ligand Pharmaceuticals’s revenue for the quarter was up 43.6% on a year-over-year basis. Analysts expect that Ligand Pharmaceuticals Incorporated will post $2.95 earnings per share for the current fiscal year.
TRADEMARK VIOLATION NOTICE: This article was reported by TheOlympiaReport and is the sole property of of TheOlympiaReport. If you are viewing this article on another website, it was copied illegally and reposted in violation of US & international copyright & trademark law. The correct version of this article can be viewed at https://theolympiareport.com/2017/08/27/ligand-pharmaceuticals-incorporated-lgnd-shares-bought-by-willingdon-wealth-management.html.
A number of equities analysts recently commented on LGND shares. Zacks Investment Research cut Ligand Pharmaceuticals from a “hold” rating to a “strong sell” rating in a report on Monday, May 15th. BidaskClub cut Ligand Pharmaceuticals from a “strong-buy” rating to a “buy” rating in a report on Wednesday, July 19th. Deutsche Bank AG reaffirmed a “hold” rating and issued a $103.00 target price (up from $100.00) on shares of Ligand Pharmaceuticals in a report on Monday, July 17th. Roth Capital set a $120.00 target price on Ligand Pharmaceuticals and gave the stock a “buy” rating in a report on Monday, May 22nd. Finally, ValuEngine raised Ligand Pharmaceuticals from a “sell” rating to a “hold” rating in a report on Thursday, June 22nd. Four analysts have rated the stock with a hold rating and four have given a buy rating to the company. Ligand Pharmaceuticals presently has an average rating of “Buy” and a consensus price target of $133.71.
In other Ligand Pharmaceuticals news, CEO John L. Higgins sold 12,000 shares of the business’s stock in a transaction that occurred on Friday, June 9th. The shares were sold at an average price of $114.87, for a total transaction of $1,378,440.00. Following the completion of the sale, the chief executive officer now directly owns 151,171 shares in the company, valued at $17,365,012.77. The transaction was disclosed in a legal filing with the SEC, which is available through this link. Also, VP Charles S. Berkman sold 18,625 shares of the business’s stock in a transaction that occurred on Wednesday, August 9th. The stock was sold at an average price of $126.96, for a total transaction of $2,364,630.00. Following the sale, the vice president now owns 24,423 shares of the company’s stock, valued at $3,100,744.08. The disclosure for this sale can be found here. Over the last quarter, insiders have sold 48,874 shares of company stock valued at $6,022,156. 14.70% of the stock is owned by insiders.
Ligand Pharmaceuticals Company Profile
Ligand Pharmaceuticals Incorporated (Ligand) is a biopharmaceutical company that focuses on developing and acquiring technologies that help pharmaceutical companies discover and develop medicines. The Company is involved in the development and licensing of biopharmaceutical assets. The Company employs research technologies, such as nuclear receptor assays, high throughput computer screening, formulation science, liver targeted pro-drug technologies and antibody discovery technologies to assist companies in their work toward obtaining prescription drug approvals.
Want to see what other hedge funds are holding LGND? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Ligand Pharmaceuticals Incorporated (NASDAQ:LGND).
Receive News & Ratings for Ligand Pharmaceuticals Incorporated Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Ligand Pharmaceuticals Incorporated and related companies with Analyst Ratings Network's FREE daily email newsletter.